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adverse clinical o 
dial ischemia wou 
survival and clinical outcome (6). Although conceptually 
such a therapeutic strategy might sound attractive, there has 
been no large-scale, well controlled clinical trial to support 
the notion that suppression f asymptomatic cardiac isch- 
ernia is of benefit n improving the associated poor progno- 
sis. Two reports in this issue of the Journai provide seminal 
*Editorials published in Journal of the American College of Cardiology 
reflect the views of the authors and do not necessarily represent the views of 
JACC or the American College of Cardiology. 
From the University of California San Francisco School of Medicine and 
the Veterans Administration Medical Center, Fresno, California. 
: Dr. Prakash C. Deedwartia, Chief, Car- 
diology Section, VA Medical Center, 2615 E. Clinton, Fresno, CA 93703. 
to assess 
ed cr~te~~~ in whit 
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d by the findings of 
another recent study (10). 
rtant finding described by Pepine t al. (7) 
r selection it is quite feasible to identify 
ptomatic ischemia during 
ambulatory ECG monitoring with a high degree of success. 
Of the 1,959 patients who qualified for ambulatory ECG 
monitoring, 952 (49%) were found to have one or more 
episode of ischemic ST segment changes on Y 
ECG monitoring. The 49% prevalence rate of as C 
characteristics and 
tion and enrollmen 
accounted for a lower prevalence of ischemia during ambu- 
latory ECG monitoring inanother recently pubhshed study 
(11). 
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The report by Knatterud et al. (8) describes the compar- 
ative safety and efficacy of three different treatment s rate- 
gies used in the ACIP study for suppression f myocardial 
ischemia. In this report of the largest prospective and 
randomized trial published todate in patients with coronary 
artery disease and asymptomatic is hemia, the investigators 
evaluated the benefits of ischemia-guided rug therapy ver- 
sus treatment with drugs titrated for control of symptoms 
(angina-guided strategy) and compared the efficacy of anti- 
ischemic drugs with that achieved with the revascularization 
strategy in eliminating ischemia during ambulatory ECG 
combinations chosen for the study consisted of
anti-ischemic agents previously proved to have a high degree 
of efficacy in suppressin myocardial ischemia. Although 
there are some legitimate oncerns about he randomization 
procedure used in the study, the available r sults do provide 
interesting information. The percent of patients who were 
free of &hernia on ambulatory ECG monitoring during 
randomized treatment was comparable in the group assigned 
to the angina-guided strategy versus those assigned to the 
ischemia-guided strategy, despite the obvious attempt to 
titrate drug therapy for suppression f all ischemic episodes 
on repeat ambulatory ECG monitoring at 4- and 8-week 
follow-up visits in the ischemia-guided strategy. Whereas the 
persistence of ischemia in the group assigned to angina- 
guided strategy is in line with previous observations (2,3), 
the high rate of persistent ischemia on ambulatory ECG 
monitoring inthe ischemia-guided strategy isclearly disap 
pointing and could be a result of some design flaws that 
deserve attention. It is clear that the titration of drugs and 
their combination was not ressive nough, as evidenced 
by only a modest reductio n mean heart rates recorded on 
ambulatory ECG monitori during therapy. More than half 
of the patients assigned to drug therapy strategies were 
either eceiving one drug or no anti-ischemic drug therapy at 
the 12-week visit (8). It is not clear why 16% of the patients 
assigned tothe ischemia-guided strategy were not given any 
drug therapy at all. The dosages ofanti-ischemic drugs used 
in both groups were also relatively modest and not large 
enough for ischemia suppression. Although the average daily 
dose of atenolol in the ischemia-guided group was higher 
than the small dose (61 mg/day) used in the group assigned to
angina-guided strategy, several previous tudies have indi- 
cated that significantly arger doses of beta adrenergic- 
blocking agents are needed to achieve maximal success in 
eliminating ischemic episodes during daily life (12,13). AS 
pointed out by Knatterud etal., the titration period allowed 
in the study was quite short, and the schema selected did not 
allow an option for higher dosages. Also, it is conceivable 
that some patients would have required all three classes of 
~Gchemic drugs given in maximally tolerated dosages to 
suPPress all ischemic episodes. Another important finding 
from the ACIP study is that treatment with atenolol and 
nifedipine-XL in combination was significantly more ef- 
fective in totally suppressing ischemia when compared with 
the diltiazem and isordil combination 447% vs. 32% iscb- 
nifedipine-Xl combination could 
most effective anti-ischemic 
cardial ischemia (12,13). An a 
practical importance in the 
ischemia at the Itweek 
that 45% of patients assi 
IZweek ambulatory ECG monitoring evaluations, 58 (41%) 
were ischemia free, suggesting that bypass surgery may 
indeed be superior to angioplasty if the primary goal of 
therapy isto sus ic episodes. 
~~i~~o~ of Although the results of the 
ACIP study provide clinically relevant and useful informa- 
tion, there are some limitations that deserve attention. First, 
most of the patients enrolled were older white men, and thus 
the data obtained may not necessarily be applicable toall 
patients with asymptomatic cardiac ischemia. Also, because 
only IS% of the patients enrolled were women, the study 
does not allow comparison ofclinical characteristics based 
on gender differences. Although the investigators have pro- 
vided reasons for exclusion of nearly one-third of patients 
eligible for ambulatory ECG monitoring, this could intro- 
duce a selection bias and should have been avoided by more 
careful attention at screening before the qualifying ambula- 
tory ECG monitoring was done. There could also be a 
selection bias toward aspecific drug combination because a 
large number (n = 255) of patients randomized to drug 
therapy were assigned to specific treatment based on physi- 
cian preference and not the randomization sequence. Whereas 
it might be necessary to avoid certain drugs (e.g., beta-blockers 
in patients with chronic obstructive pulmonary disease), the 
value of the randomization procedure is diminished if a large 
number of patients receive nonrandomized therapy. Similar 
limitations exist for those randomized to receive the revascu- 
egy, which should preferably consist of bypass surgery 
because of its superiority in eli ating ischemia, s dem- 
onstrated inthe ACIP study (8). the basis of the results of 
the ACIP study, such a scheme would not only appear to be 
logical but would constitute the most effective treatment 
strategy, which is essential to test the ischemia suppression 
Ies. Although at present there 
from other studies imilar to 
there are three major randomized trials in this 
ave been recently completed. The Atenolol Silent 
Ischemia Trial (ASIST) (14) was conducted toevaluate the 
effects of atenolol versus placebo n ischemia suppression 
and clinical outcome in asymptomatic or minimally symp- 
tomatic patients with proved coronary artery disease, xer- 
cise-induced ischemia nd evidence of asymptomatic is h- 
versus those enr 
e exercise-induce 
Canadian Amlodipine Silent Ischemia Study (CASE) (16) in 
which 120 patients with coronary artery disease stable 
angina were randomized to receive ither aml ine or 
atenolol or their combination. 
results of CASIS have not yet bee 
message from the successful enrol 
lation in these studies, including the ACIP study, is that it is 
indeed feasible to identify and enroll patients with coronary 
artery disease asymptomatic cardiac ischemia. 
ia s 
emia s~p~ressiom h 
basis of logical thinking that 
ischemia s predictive ofan increase 
and cardiac death, 
associated with an 
attractive concept, he ischemia suppression hypothesis needs 
to be proved before popularizing it because the experience 
from the Cardiac Arrhythmia Suppression Trials has certainly 
taught us an important lesson by showing that some remedies 
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are worse than the disease. To date, the only evidence avail- 
able in support of the ischemia suppression hypothesis is the 
Ming in the ASIST study that demonstrated that he suppres- 
sion of ischemia was indeed the most powerful predictor f
event-free survival at 1 year in that study. The data from 
studies like ASIST do suggest that suppression of ischemia s 
beneficial nd results in improved outcome. 
ever, are needed before the ischemia s 
l 
The results of the ACIP study (7,g) 
s from other clinical trials (14,15) 
atic cardiac ischemia does 
introduction of newer theoretic 
cans have chronic coronary artery disease, and many of 
them have evidence ofasymptomatic is hemia, it is crucial 
to find an accurate answer to this critical question i a timely 
manner. Clearly, the only way to prove or disprove the 
ischemia suppression hypothesis is to conduct a full 
clinical trial planned by the National Heart, Lung, and 
Institute. 
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